You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Screen for hepatitis B virus in all cancer patients starting systemic treatment. Find out more about hepatitis B virus screening and management.

Drug Formulary
About the Drug Formulary Email Drug Formulary Team
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Removed prior authorization for bendamustine funding

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Modified Rationale/uses section; Removed bortezomib NDFP funding info

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Modified Rationale/uses section; Removed bortezomib NDFP funding info

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Removed "Unfunded" info from bendamustine

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Modified Rationale/uses and Pregnancy/Lactation sections, Removed bortezomib NDFP funding info

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:
Regimen Monograph: Modified Rationale/uses section; Removed bendamustine NDFP funding info
Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Removed "Unfunded" info from bendamustine

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Modified Rationale/uses section; Removed bendamustine NDFP funding info

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:
Regimen Monograph: Modified Rationale/uses and Pregnancy/Lactation sections, Removed bortezomib NDFP funding info
Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Modified Rationale/uses section; Removed "Unfunded" info from bortezomib

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Modified Rationale/uses section; Removed bortezomib NDFP funding info

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Modified Rationale/uses section; Removed bortezomib NDFP funding info

Updated
Mar 2026

Pages